Effect of renal function impairment of iproplatin pharmacokinetics and relation to toxicity.
The pharmacokinetics of iproplatin, a quadrivalent second-generation platinum complex the dose-limiting toxicity of which is myelosuppression, was studied in patients with different degrees of renal function impairment. The drug was administered in a 30-min i.v. infusion. The plasma decay of iproplatin was biphasic, with an overall median terminal phase half-life of 3.16 +/- 2.6 (SD) h. The overall mean volume of distribution (Vss) was 39.9 +/- 25.0 liters, with a total body clearance of 14.25 +/- 3.99 liters/h. The total body clearance of iproplatin showed a linear correlation, with renal function measured as creatinine clearance. The toxicity of the drug, expressed as percentage of reduction in platelet count, correlated linearly with the area under the concentration X time curve.[1]References
- Effect of renal function impairment of iproplatin pharmacokinetics and relation to toxicity. Pendyala, L., Madajewicz, S., Creaven, P.J. Cancer Res. (1985) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg